<SEC-DOCUMENT>0001193125-21-108470.txt : 20210407
<SEC-HEADER>0001193125-21-108470.hdr.sgml : 20210407
<ACCEPTANCE-DATETIME>20210407120458
ACCESSION NUMBER:		0001193125-21-108470
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210407
FILED AS OF DATE:		20210407
DATE AS OF CHANGE:		20210407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		21811343

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d257557d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of April 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission
File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&nbsp;&#9744;</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;7, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> in Patients with Advanced or Metastatic Solid
Tumors</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d257557dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g257557logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio Announce First Patient Dosed in Phase 1 Trial
of Bispecific Antibody <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> in Patients with Advanced or Metastatic Solid Tumors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI,
China, GAITHERSBURG, MD, and SEONGNAM, South Korea &#150; April</B><B></B><B>&nbsp;6, 2021 &#151;</B> <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the
discovery, development and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter &#147;ABL&#148;), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the first patient has been
dosed in a phase 1 trial for bispecific antibody <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503.</FONT> The phase 1 clinical trial is an open-label, multi-center, dose-escalation and dose-expansion study to evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), preliminary antitumor activity, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> in locally advanced or metastatic solid
tumors (NCT04762641). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Being developed jointly with ABL, <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> is a differentiated <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> bispecific antibody with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> arm as the tumor-dependent <FONT STYLE="white-space:nowrap">T-cell</FONT> activator and
the <FONT STYLE="white-space:nowrap">4-1BB</FONT> arm as the conditional T cell activator upon tumor engagement. Using ABL&#146;s <FONT STYLE="white-space:nowrap">&#145;Grabody-T&#146;</FONT> bispecific antibody platform technology, <FONT
STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> stimulates <FONT STYLE="white-space:nowrap">4-1BB</FONT> activation only in the presence of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing tumor cells to minimize the risk of <FONT
STYLE="white-space:nowrap">off-tumor</FONT> toxicity. Preclinical studies have demonstrated that the bispecific antibody shows better anti-tumor activity than equimolar doses of single agents alone or in combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Immune checkpoint inhibitors, such as <FONT STYLE="white-space:nowrap">PD-L1,</FONT> have created a new paradigm for cancer treatment; however, they
have limitations in their efficacy and response rates,&#148; said Dr.&nbsp;Joan Shen, CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> <FONT STYLE="white-space:nowrap">&#147;Co-targeting</FONT> of <FONT STYLE="white-space:nowrap">PD-L1</FONT>
with a bispecific antibody molecule using this particular platform is postulated to enhance antitumor activity while ensuring the safety of the patients. It may provide an alternative therapeutic approach for patients who have not responded to
existing treatments.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased to advance the clinical development of <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> as
planned.,&#148; said Dr.&nbsp;Sang Hoon Lee, CEO of ABL. &#147;With phase 1 trial for <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503</FONT> being the first testbed for our <FONT STYLE="white-space:nowrap">Grabody-T</FONT> bispecific antibody
platform, we look forward to validating our company&#146;s technology in the field of cancer immunotherapy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to be the first
center to conduct this study for <FONT STYLE="white-space:nowrap">TJ-L14B/ABL503,&#148;</FONT> said Dr.&nbsp;Anthony&nbsp;W. Tolcher, FRCPC, FACP, CEO and director of clinical research at NEXT Oncology.
<FONT STYLE="white-space:nowrap">&#147;TJ-L14B/ABL503</FONT> has demonstrated potential to overcome the adverse toxicity issues of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-4-1BB</FONT></FONT> antibodies. In
collaboration with <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL, we hope for a thorough evaluation to deliver a highly promising treatment for the benefit of cancer patients.&#148; NEXT Oncology is a phase 1 center in the U.S. dedicated to
providing patients with advance cancer access to the newest cancer treatments available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The
Company&#146;s mission is to bring transformational medicines to patients around the world through drug innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 15 clinical and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by its internal R&amp;D capability and global licensing partnerships, based on the Company&#146;s unique
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global
R&amp;D capabilities, a world-class GMP manufacturing facility and commercialization capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China,
and Maryland and San Diego in the United States. For more information, please visit&nbsp;<U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U>&nbsp;and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT>
on&nbsp;<U>LinkedIn</U>,&nbsp;<U>Twitter</U>&nbsp;and&nbsp;<U>WeChat</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g257557logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ABL Bio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases.
With internal R&amp;D and global partnerships, ABL has developed multiple BsAb platforms, such as <FONT STYLE="white-space:nowrap">&#145;Grabody-T,&#146;</FONT> <FONT STYLE="white-space:nowrap">&#145;Grabody-I&#146;</FONT> and <FONT
STYLE="white-space:nowrap">&#145;Grabody-B&#146;</FONT> and built an innovative pipeline of multiple clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates. In the oncology area, we have developed <FONT
STYLE="white-space:nowrap">Grabody-T,</FONT> a modular <FONT STYLE="white-space:nowrap">4-1BB</FONT> engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed <FONT
STYLE="white-space:nowrap">Grabody-B</FONT> platform, which is designed to maximize blood-brain barrier (BBB) penetration. <FONT STYLE="white-space:nowrap">Grabody-B</FONT> is applicable to various CNS targets across a plethora of neurological
disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit&nbsp;www.ablbio.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding data from the <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> clinical trials, the potential implications of clinical data for patients, and the advancement by <FONT STYLE="white-space:nowrap">I-Mab</FONT> and
ABL, and anticipated clinical development, regulatory milestones and commercialization of <FONT STYLE="white-space:nowrap">TJ-L14B.</FONT> Actual results may differ materially from those indicated in the forward-looking statements as a result of
various important factors, including but not limited to the ability of <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL to demonstrate the safety and efficacy of <FONT STYLE="white-space:nowrap">TJ-L14B;</FONT> the clinical results for the drug
candidate, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the drug candidate; the ability to achieve commercial success
for the drug candidate, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance
on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional
funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other
operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as
discussions of potential risks, uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on
information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABL Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release contain &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform act of 1995.
Words such as &#147;will,&#148; &#147;could,&#148; &#147;hope,&#148; &#147;expect,&#148; &#147;plan&#148; and similar expressions that are based on ABL&#146;s current expectations and assumptions are subject to risks and uncertainties that are
difficult to predict. The risks and uncertainties include but are not limited to, potential delays in clinical trial recruitment and participation; ABL and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and
efficacy of ABL503; adverse results in the clinical development process; changes in expected or existing competition; changes in the biopharmaceutical landscape; ABL&#146;s ability to obtain and maintain protection of intellectual property for its
technology and drugs; ABL&#146;s reliance on third parties to conduct drug development; the company&#146;s financial position; future decisions by the FDA or other regulatory authorities; volatile global economic conditions; and the impact of the
global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The reader is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to ABL and the
company assumes no obligation to provide public updates to these forward-looking statements that are only as of the date of this press release, even if new information is available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g257557logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Gigi Feng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Communications Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">+86 21 6057 8000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Inquiries</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;</FONT><U>emilie@thepiacentegroup.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ABL Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jaecheon Jerry Lee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>business.development@ablbio.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+82 31 8018 9802</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Inquiries</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hyunjun Kim</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>investor.relations@ablbio.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+82 31 8018 9845</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g257557logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g257557logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!X17AI9@  34T *@    @ !@$Q  (
M   1    5@,!  4    !    : ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q     !-:6-R;W-O9G0@3V9F:6-E
M 8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'
M!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#
M!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,#/_  !$( #@ FP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MSYX-\:W%E%IL_BC2H-1>UC<R+ 9%#;0Q )QGK7Q'^V__ ,%V)_V7_P!I;7_
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M3&<+V!.>3@>'<UQ'P\L3/KIEV_+;QD].YX']:[F&&2XE6-%9F8X '>O\OOI
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>KZ@]4**** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
